Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
17 October 2018Website:
http://si-bone.comNext earnings report:
12 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
SIBN Latest News
Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws.
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.
The consensus price target hints at a 64.5% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Andrew Ranieri - Morgan Stanley Xuyang Li - Jefferies Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Si-Bone (SIBN) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024
- 1(current)
- 2
What type of business is SI-BONE?
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
What sector is SI-BONE in?
SI-BONE is in the Healthcare sector
What industry is SI-BONE in?
SI-BONE is in the Medical Devices industry
What country is SI-BONE from?
SI-BONE is headquartered in United States
When did SI-BONE go public?
SI-BONE initial public offering (IPO) was on 17 October 2018
What is SI-BONE website?
https://si-bone.com
Is SI-BONE in the S&P 500?
No, SI-BONE is not included in the S&P 500 index
Is SI-BONE in the NASDAQ 100?
No, SI-BONE is not included in the NASDAQ 100 index
Is SI-BONE in the Dow Jones?
No, SI-BONE is not included in the Dow Jones index
When was SI-BONE the previous earnings report?
No data
When does SI-BONE earnings report?
The next expected earnings date for SI-BONE is 12 November 2024